Guggenheim lowered the firm’s price target on Nautilus Biotechnology (NAUT) to $2.50 from $4 and keeps a Buy rating on the shares. A key area ...
Announced strategic expansion into AI-driven HPC hosting with long-term data center leases expected to generate $1 billion in cumulative revenue ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback